Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03001076 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
A Phase 3 study of Atherosclerosis and Hypercholesterolemia, sponsored by Esperion Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 269
- Enrollment target
- 1
- Study location
NCT03001076: Completed Phase 3 study of Atherosclerosis and Hypercholesterolemia, sponsored by Esperion Therapeutics.
NCT03001076 is a Phase 3 study of Atherosclerosis and Hypercholesterolemia that has completed, run by Esperion Therapeutics. The registered enrollment target is 269 participants, below the 1,062-participant average among 69 other Atherosclerosis trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03001076, a Phase 3 study of Atherosclerosis and Hypercholesterolemia, has completed, sponsored by Esperion Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 269 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
Primary Outcome
Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from the last two non-missing values on or prior to Day 1. Percent change from baseline was calculated as: (\[LDL-C value at Week 12 minus Baseline value\] divided by \[Baseline Value\]) multiplied by 100. Bempedoic Acid = BA. Percent change from Baseline in LDL-C was analyzed using an analysis of
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ezetimibe
- DRUG Bempedoic acid
Study Locations (1)
Texas
- - Georgetown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 269 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2018-02-12 |
| Phase | Phase 3 |
What the finished NCT03001076 record still lists
NCT03001076 is an interventional study that assigns participants to a tested intervention. The registered 269 participants enrollment target is mid-sized for trials with a published cap, below the 1,062-participant average among 69 other Atherosclerosis trials with a reported enrollment target (75% lower).
The record links to 3 conditions, with Atherosclerosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03001076 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03001076 about?
NCT03001076 is a clinical study titled "Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)". The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.
What is the current status of trial NCT03001076?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 269 participants. The study started on 2016-11-29. Estimated completion is 2018-02-12.
What conditions does trial NCT03001076 study?
This clinical trial studies the following conditions: Atherosclerosis, Hypercholesterolemia, Statin Adverse Reaction.
What interventions are being tested in trial NCT03001076?
The interventions under investigation include: Placebo (OTHER), Ezetimibe (DRUG), Bempedoic acid (DRUG).
Who is sponsoring clinical trial NCT03001076?
This trial is sponsored by Esperion Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03001076 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03001076's enrollment target sits among peer trials
269 31st of 69 higher than 39 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
COMPLETED · Phase 3
-
RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty
COMPLETED · Phase 3
-
12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe
COMPLETED · Phase 3
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04802291 · 269 participants · NA
HomeStyles-2: Shaping HOME Environments and LifeSTYLES to Prevent Childhood Obesity
- NCT06500455 · 269 participants · Phase 3
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
- NCT06630676 · 269 participants · NA
The Ability of Chronic Pain Patients to Self-diagnose Their Chief Source of Low Back Pain
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI